Biodesix: Growing Fast While Trading Below Many Diagnostics Peers

Biodesix is gaining momentum in lung diagnostics, with >30% revenue growth and accelerating test volumes. BDSX boasts 80%+ gross margins and improving operating leverage, supporting a credible path to profitability despite ongoing cash burn. The stock trades at a discounted EV/Sales multiple versus peers, despite industry-leading gross margins and robust clinical evidence.